COMMUNIQUÉS West-GlobeNewswire

argenx to Host Autoimmune Myositis R&D Webinar
23/06/2026
June 23, 2026, 7:00 AM CET Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, will host a [...]
Press Release: Sanofi’s Wayrilz approved in Japan to treat immune thrombocytopenia
23/06/2026
Sanofi’s Wayrilz approved in Japan to treat immune thrombocytopenia Wayrilz is a BTK inhibitor that works through multi-immune modulation to help address the underlying causes of immune thrombocytopenia (ITP) Approval [...]
Communiqué de presse : Cenrifki (tolebrutinib) de Sanofi approuvé dans l’UE comme premier médicament ciblant la progression du handicap dans la sclérose en plaques secondairement progressive sans rechutes
23/06/2026
Cenrifki (tolebrutinib) de Sanofi approuvé dans l’UE comme premier médicament ciblant la progression du handicap dans la sclérose en plaques secondairement progressive sans rechutes Cenrifki représente une avancée [...]
COSCIENS Biopharma Inc. Announces Details of Share Capital Amendment
23/06/2026
TORONTO, ONTARIO, June 22, 2026 (GLOBE NEWSWIRE) -- COSCIENS Biopharma Inc. (TSX: CSCI) (OTCQB: CSCIF) (“ COSCIENS ” or the “ Company ”) announced the next steps in connection with changes to the Company’s share capital [...]
Sagimet Biosciences Announces Participation in Upcoming Investor Conference and Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
23/06/2026
SAN MATEO, Calif., June 22, 2026 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic [...]
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)
22/06/2026
CONSHOHOCKEN, Pa., June 22, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated [...]
CervoMed Announces Closing of $10 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules
22/06/2026
BOSTON, June 22, 2026 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical-stage biotechnology company developing treatments for age-related brain disorders (CervoMed or the Company), today announced the closing [...]
IMUNON to Present at the Life Sciences Investor Forum on June 25th
22/06/2026
LAWRENCEVILLE, N.J., June 22, 2026 (GLOBE NEWSWIRE) -- IMUNON , Inc. (NASDAQ: IMNN) , a clinical-stage company in Phase 3 development with its DNA-mediated immunotherapy, today announced that Stacy Lindborg, Ph.D., [...]
Vivani Medical CEO Adam Mendelsohn to Present at the 2026 BIO International Convention
22/06/2026
ALAMEDA, Calif., June 22, 2026 (GLOBE NEWSWIRE) -- Vivani Medical, Inc. ( NASDAQ: VANI ) (“Vivani” or the “Company”), a clinical-stage biopharmaceutical company developing miniature, ultra long-acting drug implants, [...]
uniQure Announces $150 Million Proposed Public Offering
22/06/2026
LEXINGTON, Mass. and AMSTERDAM, June 22, 2026 (GLOBE NEWSWIRE) -- uniQure N.V. (Nasdaq: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced [...]
Transactions of Managers and Closely Associated Persons
23/06/2026
Attached is a copy of a filing with the Luxembourg Commission de Surveillance du Secteur Financier (CSSF) regarding transactions of managers and closely associated persons, announcing the acquisition of 10,133,333 [...]
Pioneering screening test offers potential to find more aggressive prostate cancers
22/06/2026
Annals of Internal Medicine publishes study showing potential benefits of Stockholm3 in identifying patients with aggressive prostate cancer STOCKHOLM, June 22, 2026 (GLOBE NEWSWIRE) -- A3P Biomedical, a diagnostics [...]
MacroGenics to Receive Milestone Payment from Sanofi for Recent TZIELD® Approval
22/06/2026
ROCKVILLE, MD, June 22, 2026 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on developing innovative antibody-based therapeutics for the treatment of cancer, [...]
Acquisition of Centessa by Lilly Approved by the High Court of Justice of England and Wales
22/06/2026
BOSTON and LONDON, June 22, 2026 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage company developing a new class of medicines for the treatment of excessive daytime sleepiness and other [...]
The Health Institute Announces Heal Your Cells, a New Book by Dr. Josh Axe and Dr. Will Cole on Cellular Health and Healthy Aging
23/06/2026
Inspired by personal loss and years of clinical practice, the forthcoming release explores how cellular function may influence energy, wellness, and long-term health. Nashville, June 22, 2026 (GLOBE NEWSWIRE) -- The [...]
Elevar Therapeutics Announces First Patients Dosed in Phase 2 Study of Lirafugratinib Among Non-CCA Solid Tumors With FGFR2 Fusion or Rearrangement
22/06/2026
First patient was dosed at Samsung Medical Center in Seoul, South Korea; a second at Moffitt Cancer Center in Tampa, Florida Global multi-site study includes locations in U.S., Korea, the UK, Spain, and France Study [...]
Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
22/06/2026
BEDFORD, Mass., June 22, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular” or the “Company”), an integrated biopharmaceutical company committed to redefining the retina experience, today [...]
Dyne Therapeutics Appoints Barry Greene to Board of Directors
22/06/2026
WALTHAM, Mass., June 22, 2026 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular [...]
MoonLake Immunotherapeutics Announces Proposed Public Offering
22/06/2026
ZUG, Switzerland, June 22, 2026 – MoonLake Immunotherapeutics (NASDAQ: MLTX) (“MoonLake”), a clinical-stage biotechnology company focused on creating next-level therapies for inflammatory skin and joint diseases, today [...]

Pages